AdvanBio is Committed To The Advancement Of Medical Laboratory Technology And Dedicated To The Promotion Of Human Health.

At AdvanBio, developing meaningful solutions targeted at improving patient diagnosis is our top priority.   AdvanBio specializes in R&D, providing service of clinical diagnostic products, especially covering molecular technology, immunoassay, microbiology, and clinical biochemistry fields.  AdvanBio is actively planning the developments in the field of molecular diagnostics and provides a comprehensive solution for medical laboratories.  With our distinct approach to R&D and a dedicated expert team, we facilitate breakthroughs in diagnostics with innovative platforms by integrating emerging technologies with a deep understanding of biological materials.

Our parent company is listed on Shanghai, Stock Exchange on September 1st, 2016, which is the first IVD manufacturer listed on the mainboard in Shanghai, China.  We have 23 years of experience in Research and Development, $459 million operating income in 2020, and 5000+ employees worldwide.   We highly value the importance of product R&D and technological innovation.   The annual average R&D investment exceeds 10% in recent years.   We apply strict research and development process management; focusing on the research and development of core raw materials, we have created a diagnostic antibody library for tens of thousands of antigen epitopes, with over 73% self-supply for antigen and antibody, which ensures the stability and safety of supply. We have become one of the leading companies with the most registered products and the most comprehensive product catalog in China.  Our marketing network covers the whole China, and our products have entered more than then thousands of medical institutions and are widely sold to 80+ countries and regions.